Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center

To evaluate safety, efficacy, and feasibility of apixaban for postoperative venous thromboembolism (VTE) prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. This retrospective, cohort study included patients with gynecologic cancer who underwent open surgery betwe...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2024-04, Vol.183, p.120-125
Main Authors: Knisely, Anne, Iniesta, Maria D., Batman, Samantha, Meyer, Larissa A., Soliman, Pamela T., Cain, Katherine E., Marten, Claire, Chisholm, Gary, Schmeler, Kathleen M., Taylor, Jolyn S., Fleming, Nicole D.
Format: Article
Language:English
Subjects:
Apixaban
Enoxaparin
Gynecologic cancer
Thromboembolism prophylaxis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate safety, efficacy, and feasibility of apixaban for postoperative venous thromboembolism (VTE) prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. This retrospective, cohort study included patients with gynecologic cancer who underwent open surgery between 3/2021 and 3/2023 and received 28-day postoperative VTE prophylaxis. Patients on therapeutic anticoagulation preoperatively were excluded. Predictors of 90- and 30-day VTE and 30-day bleeding events were determined using multivariable logistic regression, adjusting for known confounders. 452 patients were included in the cohort: 348 received apixaban and 104 received enoxaparin. Those who received enoxaparin were more likely to be American Society of Anesthesiologists class III/IV (compared to I/II) (p = 0.033), current or former smokers (p = 0.012) and have a higher BMI (p 
ISSN:0090-8258
1095-6859
1095-6859
DOI:10.1016/j.ygyno.2024.01.039